Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Lung Disease Clinical Trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (3276) clinical trials

This is a placebo controlled trial to test the efficacy and safety of CHF 5259 (glycopyrronium bromide). This is an 8 week treatment trial.

Phase

A global registry to study the demographics, socioeconomic and clinical factors, etiologies, pathophysiology, management, barriers to care, and outcomes of heart failure patients.

Phase N/A

A research study is evaluating the effects of an investigational study medication for heart failure in patients with iron deficiency.

Phase N/A

To evaluate the safety and efficacy of a once daily oral medication compared to a placebo, in patients with chronic Heart Failure with preserved Ejection Fraction.

Phase

This is a multicenter, open-label, multi-arm Phase 2 study to evaluate the efficacy and safety of single agent niraparib in patients with locally advanced and metastatic sqNSCLC and of the combination of niraparib and pembrolizumab in locally advanced and metastatic NSCLC (all histologies) patients. 

Phase N/A

People with non-small cell lung cancer are asked to participate in a research study being conducted by White Plains Hospital.

Phase N/A

People with suspicion of lung cancer who are scheduled for a biopsy/other diagnostic procedure are asked to participate in a research study being conducted by Long Island Jewish Medical Center.

Phase N/A

The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens for use in assessing new biomarkers for the detection of neoplasms of the lung.

Phase N/A

To evaluate the effect of treatment with omecamtiv mecarbil (OM) compared with placebo on the time to cardiovascular (CV) death or first HF (Heart Failure) event, whichever occurs first, in subjects with chronic HF with reduced ejection fraction (HFrEF) receiving standard of care (SoC) therapy.

Phase N/A

To evaluate the efficacy of the oral soluble guanylate cyclase (sGC) stimulator MK-1242 (vericiguat) in comparison to placebo on a background of standard of care in increasing the time to first occurrence of the composite of CV death or HF hospitalization in subjects with HFrEF.

Phase N/A